Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO) (HY196226)

Name: Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO)
Brand: abinScience
SKU: HY196226
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY196226
Description	Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO) (HY196226) is a human monoclonal antibody detecting HGFR/c-MET.
Species reactivity	Human
Applications	ELISA, FACS, Functional assay
Host species	Human
Clonality	Monoclonal
Isotype	IgG2, kappa
Target	EC:2.7.10.1, HGF receptor, HGF/SF receptor, Hepatocyte growth factor receptor, MET, Proto-oncogene c-Met, SF receptor, Scatter factor receptor, Tyrosine-protein kinase Met
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P08581
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term from the date of receipt..
Alternate Names	CAS: 3076369-09-7
Background	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Note	For research use only.